H. Lundbeck A/S - Product Pipeline Review - 2016

  • ID: 3674247
  • Company Profile
  • 59 pages
  • Global Markets Direct
  • H. Lundbeck A/S
1 of 4
H. Lundbeck A/S - Product Pipeline Review - 2016

Summary

‘H. Lundbeck A/S - Product Pipeline Review - 2016’, provides an overview of the H. Lundbeck A/S’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by H. Lundbeck A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of H. Lundbeck A/S
- The report provides overview of H. Lundbeck A/S including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses H. Lundbeck A/S’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features H. Lundbeck A/S’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate H. Lundbeck A/S’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for H. Lundbeck A/S
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding H. Lundbeck A/S’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

H. Lundbeck A/S Snapshot

H. Lundbeck A/S Overview

Key Information

Key Facts

H. Lundbeck A/S - Research and Development Overview

Key Therapeutic Areas

H. Lundbeck A/S - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

H. Lundbeck A/S - Pipeline Products Glance

H. Lundbeck A/S - Late Stage Pipeline Products

Filing rejected/Withdrawn Products/Combination Treatment Modalities

Phase III Products/Combination Treatment Modalities

H. Lundbeck A/S - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

H. Lundbeck A/S - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

H. Lundbeck A/S - Drug Profiles

carbamazepine

Product Description

Mechanism of Action

R&D Progress

idalopirdine

Product Description

Mechanism of Action

R&D Progress

LuAF-35700

Product Description

Mechanism of Action

R&D Progress

nalmefene

Product Description

Mechanism of Action

R&D Progress

vortioxetine hydrobromide

Product Description

Mechanism of Action

R&D Progress

LuAF-11167

Product Description

Mechanism of Action

R&D Progress

LUAF-20513

Product Description

Mechanism of Action

R&D Progress

LUAF-64280

Product Description

Mechanism of Action

R&D Progress

AF-40431

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Antagonize nAChR Alpha-4 Beta-2 for Brain Diseases

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit LRRK-2 for Parkinson's Disease

Product Description

Mechanism of Action

R&D Progress

H. Lundbeck A/S - Pipeline Analysis

H. Lundbeck A/S - Pipeline Products by Target

H. Lundbeck A/S - Pipeline Products by Route of Administration

H. Lundbeck A/S - Pipeline Products by Molecule Type

H. Lundbeck A/S - Pipeline Products by Mechanism of Action

H. Lundbeck A/S - Recent Pipeline Updates

H. Lundbeck A/S - Dormant Projects

H. Lundbeck A/S - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

gaboxadol

LuAA-47070

idalopirdine

Lu-02750

Lu-35138

Lu-AA24493

LuAA-37096

LuAA-38466

LuAA-39959

LuAA-44608

LuAE-04621

ORE-10002

siramesine

tedatioxetine hydrobromide

vortioxetine hydrobromide

zicronapine

H. Lundbeck A/S - Company Statement

H. Lundbeck A/S - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

H. Lundbeck A/S, Key Information

H. Lundbeck A/S, Key Facts

H. Lundbeck A/S - Pipeline by Indication, 2016

H. Lundbeck A/S - Pipeline by Stage of Development, 2016

H. Lundbeck A/S - Monotherapy Products in Pipeline, 2016

H. Lundbeck A/S - Partnered Products in Pipeline, 2016

H. Lundbeck A/S - Partnered Products/ Combination Treatment Modalities, 2016

H. Lundbeck A/S - Out-Licensed Products in Pipeline, 2016

H. Lundbeck A/S - Out-Licensed Products/ Combination Treatment Modalities, 2016

H. Lundbeck A/S - Filing rejected/Withdrawn, 2016

H. Lundbeck A/S - Phase III, 2016

H. Lundbeck A/S - Phase II, 2016

H. Lundbeck A/S - Phase I, 2016

H. Lundbeck A/S - Preclinical, 2016

H. Lundbeck A/S - Discovery, 2016

H. Lundbeck A/S - Pipeline by Target, 2016

H. Lundbeck A/S - Pipeline by Route of Administration, 2016

H. Lundbeck A/S - Pipeline by Molecule Type, 2016

H. Lundbeck A/S - Pipeline Products by Mechanism of Action, 2016

H. Lundbeck A/S - Recent Pipeline Updates, 2016

H. Lundbeck A/S - Dormant Developmental Projects,2016

H. Lundbeck A/S - Discontinued Pipeline Products, 2016

H. Lundbeck A/S, Subsidiaries

List of Figures

H. Lundbeck A/S - Pipeline by Top 10 Indication, 2016

H. Lundbeck A/S - Pipeline by Stage of Development, 2016

H. Lundbeck A/S - Monotherapy Products in Pipeline, 2016

H. Lundbeck A/S - Partnered Products in Pipeline, 2016

H. Lundbeck A/S - Out-Licensed Products in Pipeline, 2016

H. Lundbeck A/S - Pipeline by Top 10 Target, 2016

H. Lundbeck A/S - Pipeline by Route of Administration, 2016

H. Lundbeck A/S - Pipeline by Molecule Type, 2016

H. Lundbeck A/S - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll